BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B
- Conditions
- Hepatitis B
- Interventions
- Other: Non-interventional
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT03426618
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)
- Conditions
- Lung Cancer
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 764
- Registration Number
- NCT03425825
- Locations
- 🇬🇧
Local Institution, London, United Kingdom
A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
- Conditions
- Hepatic CirrhosisLiver Fibrosis
- Interventions
- Other: Placebo
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT03420768
- Locations
- 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 54
- Registration Number
- NCT03419910
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants
- Conditions
- Psoriatic Arthritis (PsA)
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 190
- Registration Number
- NCT03419143
- Locations
- 🇩🇪
Local Institution - 0001, Nurnberg, Germany
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03417037
- Locations
- 🇹🇷
Local Institution, Istanbul, Turkey
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 196
- Registration Number
- NCT03414983
- Locations
- 🇺🇸
Local Institution - 0033, Arlington Heights, Illinois, United States
🇺🇸Local Institution - 0005, Philadelphia, Pennsylvania, United States
🇺🇸Uab Comprehensive Cancer Center, Birmingham, Alabama, United States
A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Biological: MDX-010
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT03407105
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
🇺🇸Tower ID Medical Associates, Los Angeles, California, United States
A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients
- Conditions
- LupusPsoriatic Arthritis
- Interventions
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT03402087
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3
- Registration Number
- NCT03400163
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States